A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...

Under this condition, which can result from traumatic injuries, infections, metabolic problems, or could be inherited due to ...

(CNN) – The U.S. Food and Drug Administration approved the first new type of pain medication in more than two decades, and it’s not an opioid. The drug is suzetrigine under the brand name Journavx. It ...

Have you experienced pain or tingling in your hands or feet? Those are signs of possible neuropathy, “a general term for ...

Stop the debilitating symptoms of neuropathy. Make a change today with help from Advanced Nerve and Health Center.

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...